Latest Period
n/a
Security Snapshot
RECURSION PHARMACEUTICALS INC - COMMON STOCK (DNA) Institutional Ownership
CUSIP: 37611X100
13F Institutional Holders and Ownership History from Q2 2020 to Q2 2025
Institutions Reporting
Shares (Excl. Options)
Price
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / COMMON STOCK
- Symbol
- DNA on NYSE
- Shares outstanding
- 518,011,600
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- DNA - RECURSION PHARMACEUTICALS INC - COMMON STOCK is tracked under CUSIP 37611X100.
- Latest finished 13F holder period is not available.
- 2 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 1 to 0 between Q1 2025 and Q2 2025.
- SEC-reported value moved from $203,000 to $0.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Schedule 13D/G
Open SEC evidence
Ownership context comes from Schedule 13D/G and available holder history for this CUSIP.
Security key
37611X100
Latest holder period
n/a
13F holders
13D/G owners
2
CIK / CUSIP context first
DNA full holder history
RECURSION PHARMACEUTICALS, INC. SEC filings
RECURSION PHARMACEUTICALS, INC. company facts
RECURSION PHARMACEUTICALS, INC. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 37611X100:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
2
Security
DNA
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| STATE STREET CORP | 5.5% | 28,490,638 | STATE STREET CORPORATION | 31 Mar 2026 | ||||
| BAILLIE GIFFORD & CO | 6.5% | -30% | $5,718,733 | -$125,747 | 24,864,058 | -1.5% | BAILLIE GIFFORD & CO | 31 Dec 2024 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
17
Latest
n/a
Rows shown
1-17 of 17
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q2 | 0 | $0 | -$203,000 | 0 | |
| 2025 Q1 | 606,634 | $203,000 | +$203,000 | $0.33 | 1 |
| 2024 Q4 | 0 | $0 | -$128,803 | 0 | |
| 2024 Q3 | 18,945 | $125,460 | -$301,879,516 | $0.33 | 6 |
| 2024 Q2 | 932,642,413 | $311,412,586 | -$140,817,814 | $0.33 | 303 |
| 2024 Q1 | 1,295,131,199 | $1,502,666,435 | +$34,953,568 | $1.16 | 328 |
| 2023 Q4 | 1,264,067,636 | $2,135,655,316 | +$35,010,634 | $1.69 | 328 |
| 2023 Q3 | 1,240,312,565 | $2,245,097,773 | +$49,927,444 | $1.81 | 342 |
| 2023 Q2 | 1,209,022,771 | $2,248,308,746 | +$138,253,220 | $1.86 | 305 |
| 2023 Q1 | 1,138,832,894 | $1,513,754,471 | +$188,812,259 | $1.33 | 308 |
| 2022 Q4 | 994,200,228 | $1,680,167,004 | +$184,329,564 | $1.69 | 311 |
| 2022 Q3 | 878,617,048 | $2,743,130,023 | +$305,100,080 | $3.12 | 257 |
| 2022 Q2 | 787,669,463 | $1,933,096,110 | +$286,080,459 | $2.38 | 245 |
| 2022 Q1 | 666,585,740 | $2,678,164,885 | -$1,015,524,006 | $4.03 | 180 |
| 2021 Q4 | 896,807,871 | $7,383,978,168 | +$844,855,283 | $8.31 | 158 |
| 2021 Q3 | 792,062,901 | $9,177,440,180 | +$9,177,091,180 | $11.59 | 122 |
| 2020 Q2 | 15,000 | $36,000 | $2.40 | 1 |